Top Story

FDA grants orphan drug status to SL-701 for glioma treatment

January 30, 2015

The FDA today granted orphan drug designation to SL-701 for the treatment of glioma, according to a press release from the drug’s manufacturer.

SL-701 (Stemline Therapeutics) is an enhanced immunotherapy that activates the immune system to kill malignant gliomas.

Mary Ann Burg, PhD, LCSW In the JournalsPerspective

Cancer survivors' needs 'not sufficiently addressed' by medical community

January 30, 2015
Physical, financial, emotional and mental health problems persist as unmet needs in cancer survivors, according to study results. Mary Ann Burg, PhD, LCSW, professor…
In the Journals

Molecular subtypes of stage III colon cancer linked to different patient outcomes

January 30, 2015
Researchers have identified subtypes of stage III colon cancer based on molecular markers associated with differences in clinical and pathological features as well as…
Lecia V. Sequist, MD, MPH In the Journals

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

January 30, 2015
Patients with lung adenocarcinoma who harbored exon 19 deletion EGFR mutations experienced significantly longer OS when treated with first-line afatinib instead of…
In the Journals

Additional CT scans increased risk for second primary malignancy in patients with non-Hodgkin's lymphoma

January 30, 2015
Patients with non-Hodgkin’s lymphoma who underwent more frequent surveillance CT scans demonstrated an increased risk for a secondary primary malignancy, according…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan